Driven by the approval of pipeline agents, mRNA non-vaccine therapeutics are set to reach $2 billion in sales by 2028, says GlobalData.
List view / Grid view
Protocol for purification, proteolysis, reduction and UHPLC-MS analysis of unlabelled and labelled monoclonal antibodies
CPI has opened its Medicines Manufacturing Innovation Centre in Scotland to focus on efficient, sustainable manufacturing and advance medicine research.
Available on-demand: experts discussion and Q&A on the recent annex 1 revision, in the context of Microbiological Environmental Monitoring.
Personalised medicine and increased total lab automation techniques will drive the automated cell biology systems market, says Future Market Insights analyst.
A new regulatory group, part of the European Medicines Agency, will aid innovative approaches for the development and quality control of medicines, including new technologies for EU patients.
A 2022 WHO report is the first to portray COVID-19’s impact on the global vaccine market, identifying that lower-income countries struggle to access critical vaccines.
The 2022 Access to Medicine Index shows all 20 pharma companies have an over-arching access to medicine strategy, benefitting low and middle-income countries.
Over the last 10 years, there has been an important change of focus in pharma towards biotech products and personalised therapies. These important new treatments are now emerging into manufacturing, with implications for the way that quality is monitored, managed and assured. Dr Eduard Cayón sets out some practical advice.
Merck and Novatek International team up to monitor contamination and enhance environmental monitoring in the pharmaceutical industry.
Paper highlights trends in developing analytical procedures to assess the quality of prostaglandin analogues used to treat glaucoma.